CE

Cellbion Co., Ltd

Develops & manufactures radiopharmaceuticals for cancer diagnosis and therapy.

308430 | KO

Overview

Corporate Details

ISIN(s):
KR7308430008
LEI:
Country:
South Korea
Address:
서울특별시 종로구 대학로 103 서울대학교 암연구소 6층, 종로구
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Cellbion Co., Ltd. is a clinical-stage biopharmaceutical company specializing in the research, development, and manufacturing of radiopharmaceuticals. The company focuses on advancing Radioligand Therapy (RLT) and antibody-based treatments to address unmet medical needs, particularly in oncology. Its pipeline includes diagnostic imaging agents for PET CT and therapeutic drugs, with a key program targeting Prostate-Specific Membrane Antigen (PSMA) for the diagnosis and therapy of prostate cancer. Cellbion operates a GMP-certified facility for the production of liquid and lyophilized injectable products, supporting both clinical trials and commercial supply.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-12 00:00
Regulatory News Service
투자판단관련주요경영사항(임상시험계획승인신청등결정) (전이성 거세 저항성 전립선암 환자에서 Lutetium(177Lu) …
Korean 12.6 KB
2025-09-09 00:00
Report Publication Announcement
기업설명회(IR)개최
Korean 6.8 KB
2025-09-04 00:00
Regulatory News Service
투자판단관련주요경영사항(임상시험결과) (표준요법에 실패한 전이성 거세저항성 전립선암 환자에서 Lu177DGUL의 국내 …
Korean 16.8 KB
2025-08-13 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.1 MB
2025-06-23 00:00
Regulatory News Service
투자판단관련주요경영사항(임상시험계획승인신청) (전이성 거세 저항성 전립선암 환자에서 Lutetium(177Lu) DGU…
Korean 9.0 KB
2025-05-13 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 1.1 MB
2025-03-31 00:00
Post-Annual General Meeting Information
정기주주총회결과
Korean 23.1 KB
2025-03-31 00:00
Share Issue/Capital Change
주식매수선택권부여에관한신고
Korean 15.3 KB
2025-03-31 00:00
Board/Management Information
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Korean 9.9 KB
2025-03-20 00:00
Audit Report / Information
사업보고서 (2024.12)
Korean 460.8 KB
2025-03-14 00:00
Audit Report / Information
감사보고서제출
Korean 18.9 KB
2025-03-11 00:00
Report Publication Announcement
기업설명회(IR)개최
Korean 6.8 KB
2025-02-28 00:00
Pre-Annual General Meeting Information
주주총회소집결의
Korean 11.8 KB
2025-02-28 00:00
Pre-Annual General Meeting Information
주주총회소집공고
Korean 119.1 KB
2025-01-31 00:00
Earnings Release
매출액또는손익구조30%(대규모법인은15%)이상변동
Korean 11.5 KB

Automate Your Workflow. Get a real-time feed of all Cellbion Co., Ltd filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Cellbion Co., Ltd

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Cellbion Co., Ltd via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Apellis Pharmaceuticals, Inc. Logo
Developing novel C3 therapies for diseases in ophthalmology, nephrology, and hematology.
United States of America
APLS
Apimeds Pharmaceuticals US, Inc. Logo
Biopharma developing non-narcotic bee venom therapies for osteoarthritis pain and inflammation.
United States of America
APUS
Apogee Therapeutics, Inc. Logo
Developing novel antibody biologics for immunological and inflammatory (I&I) diseases.
United States of America
APGE
Apollomics Inc. Logo
A clinical-stage biopharma developing targeted oncology therapies for hard-to-treat cancers.
United States of America
APLM
Apontis Pharma AG Logo
German pharma firm specializing in Single Pills for cardiovascular and chronic diseases.
Germany
APPH
Develops DNA tech for genetic medicine, molecular diagnostics, and supply chain security.
United States of America
APDN
Applied Therapeutics, Inc. Logo
Develops treatments for rare metabolic and central nervous system (CNS) disorders.
United States of America
APLT
Aprea Therapeutics, Inc. Logo
Developing precision cancer therapies targeting DNA Damage Response for solid tumors.
United States of America
APRE
AprilBio Co.,Ltd. Logo
Develops long-acting biologic drugs for autoimmune diseases and oncology using its SAFA™ platform.
South Korea
397030
Aprogen Biologics Inc. Logo
Develops and manufactures novel biologic drugs and biosimilars for the professional market.
South Korea
003060

Talk to a Data Expert

Have a question? We'll get back to you promptly.